EXHIBIT 99.1

                                ORTHOMETRIX, INC.
                               (FORMERLY KNOWN AS
                         NORLAND MEDICAL SYSTEMS, INC.)


Company Contact:
REYNALD BONMATI - CHIEF EXECUTIVE OFFICER
914-694-2285


              NORLAND MEDICAL SYSTEMS, INC. COMPLETES SALE OF BONE
            DENSITOMETRY BUSINESS TO COOPERSURGICAL AND CHANGES NAME
                              TO ORTHOMETRIX, INC.

WHITE PLAINS, NY, APRIL 15, 2002 -- ORTHOMETRIX,  INC. (FORMERLY NORLAND MEDICAL
SYSTEMS,  INC.) (OTCBB:  OMRX)  (FORMERLY  OTCBB:  NRLD) announced today that it
completed  the sale of its bone  densitometry  business to  CooperSurgical,  the
women's  health care business of the Cooper  Companies,  Inc.  (NYSE:  COO). The
purchase price for the sale was $5 million, subject to adjustment, of which, the
Company  received $3.5 million at closing and the $1.5 million  balance of which
is being held back against  post-closing  adjustments and indemnities in respect
of representations and warranties.  In addition, the Company will be eligible to
receive an  earnout  based on the net sales of  certain  products  over a 3-year
period,  up to a  maximum  total  sales  price  of  $12  million  for  the  bone
densitometry  business.   CooperSurgical  has  assumed  only  certain  specified
liabilities related to the purchased assets.  Upon the closing,  Norland Medical
Systems, Inc. changed its name to Orthometrix, Inc.

Commenting on the transaction,  Reynald G. Bonmati, Chairman and Chief Executive
Officer of the  Company,  stated  "Our intent is to use the  proceeds  from this
transaction to reduce  remaining  liabilities and to finance the development and
regulatory approval of certain of our products for  musculoskeletal  diagnostic,
sports medicine,  rehabilitative  medicine and pain  management.  Our goal is to
reposition our Company in the attractive musculoskeletal market."

The bone densitometry business sold to CooperSurgical  involved the development,
manufacture,  sales and  service of a wide range of bone  densitometry  products
used to assess bone mineral content and density,  one of several factors used by
physicians  to  aid  in  the  diagnosis  and   monitoring  of  bone   disorders,
particularly  osteoporosis.  Under its new name, Orthometrix,  Inc., the Company
will focus on the sale,  marketing  and service of its existing  musculoskeletal
product lines, and the development of additional  musculoskeletal lines, used in
sports  medicine,  rehabilitative  medicine  and  pain  management,  as  well as
state-of-the-art  lithotripters  used in urology to treat kidney stones. Its new
Web address is www.orthometrix.net.




                                       3


"SAFE HARBOR"  STATEMENT UNDER THE PRIVATE  SECURITIES  LITIGATION REFORM ACT OF
1995: The statements  which are not historical  facts  contained in this release
are forward-looking  statements that involve risk and uncertainties,  including,
but not  limited  to, the  possibility  that the  potential  earnout  may not be
achieved,  or any effect on future financial  results from efforts to reposition
the Company in the medical  device  business,  any potential  impact on sales of
systems  for  bone  and  muscle  diagnostic,  sports  medicine,   rehabilitative
medicine, pain management,  any potential impact on sales of the systems for the
treatment  of  kidney  stones,   and  other  risks  detailed  in  the  documents
periodically filed with the Securities and Exchange Commission, specifically the
most recent reports on Forms 10-K and 10-Q. These risks and uncertainties  could
cause  actual  results to differ  from those  contained  in the  forward-looking
statements. Any forward-looking statement made in this release is made as of the
date of this  release  and the  Company  assumes no  obligation  to update  such
forward-looking statement.



                                       ###













                                       4